The overall discrepancy between our pre-clinical data and the reported clinical trials could be a consequence of glioblastoma heterogeneity, of the rapid development of resistance, as well as the sub-clonal nature of EGFR mutations in glioblastoma. This evidence concerns the gene EGFR and glioblastoma.